51 completed, 20 unknown, 9 active not recruiting, 7 not yet recruiting. 21 Phase 3, 18 Phase 4, 10 Phase 2, 5 Not applicable, 3 Phase 1.
Follow Pulmonary Eosinophilia: new trials by email Literature Review of Pulmonary Eosinophilia trials Research Report on Pulmonary Eosinophilia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma Depemokimab - Allergic Bronchopulmonary Aspergillosis, ABPA | Not applicable | Not yet recruiting | Qianfoshan Hospital | 10 | 2026-11-01 | 2026-09-24 |
| REverse LuNg Airway and Vascular RemOdeling in Asthma ReMission (ReNORM) Biologic Therapy - Asthma; Eosinophilic | Not applicable | Not yet recruiting | Western University, Canada | 200 | 2026-10-01 | 2026-07-31 |
| Fasenra: An Asthma Study Budesonide-albuterol, Benralizumab - Eosinophilic Asthma, Severe Asthma | Phase 4 | Enrolling by invitation | Endeavor Health | 40 | 2026-07-01 | 2026-09-15 |
| A Study of Depemokimab in Participants of 6 to 11 Years of Age Depemokimab - Asthma | Phase 3 | Recruiting | GlaxoSmithKline | 34 | 2026-06-25 | 2026-08-26 |
| A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma KT-621, Placebo - Eosinophilic Asthma | Phase 2 | Recruiting | Kymera Therapeutics, Inc. | 264 | 2026-01-28 | 2026-10-06 |
| A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy benralizumab - Severe Eosinophilic Asthma | Recruiting | AstraZeneca | 335 | 2025-12-20 | 2026-09-18 | |
| A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma AD17002, Formulation buffer - Eosinophilic Asthma | Phase 2 | Not yet recruiting | Advagene Biopharma Co. Ltd. | 126 | 2025-12-01 | 2025-11-26 |
| Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA Mepolizumab 100 MG Injection [Nucala], Mepolizumab 300 mg - EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma | Phase 4 | Enrolling by invitation | Azienda Ospedaliero Universitaria di Cagliari | 90 | 2025-10-17 | 2026-01-15 |
| Eosinophil Subpopulations in Eosinophilic-associated Diseases Eosinophilic Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Not yet recruiting | University of Florence | 160 | 2025-04-01 | 2025-04-04 | |
| Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment ICS-LABA, benralizumab, Placebo for Benralizumab - Eosinophilic Asthma | Phase 3 | Completed | AstraZeneca | 130 | 2025-03-28 | 2026-10-16 |
| Homeostatic Roles of Eosinophils in Asthma Blood Punction - Asthma; Eosinophilic | Not applicable | Not yet recruiting | Centre Hospitalier Universitaire de Besancon | 100 | 2024-12-04 | 2024-11-06 |
| A Non-interventional, Prospective Study With Benralizumab Asthma, Bronchial | Recruiting | AstraZeneca | 300 | 2024-07-25 | 2026-08-28 | |
| SIM0718 Treatment of Asthma Clinical Study SIM0718 injection, SIM0718 injection of placebo - Asthma; Eosinophilic | Phase 3 | Active not recruiting | Simcere Pharmaceutical Co., Ltd | 418 | 2024-06-23 | 2026-10-21 |
| Phase III Long-Term Extension Study With Dexpramipexole Dexpramipexole Dihydrochloride - Eosinophilic Asthma | Phase 3 | Terminated | Areteia Therapeutics | 509 | 2024-06-12 | 2025-12-15 |
| Clock Proteins as Prognostic Markers Severe Eosinophilic Asthma | Terminated | Medical University of Graz | 50 | 2024-05-01 | 2025-10-03 | |
| Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma Lipopolysaccharides - Asthma; Eosinophilic, Asthma | Phase 1 | Not yet recruiting | National Jewish Health | 60 | 2024-04-01 | 2024-02-21 |
| BenRalizumab Effect on Airway Remodeling in Severe asTHma Benralizumab 30 mg/ml - Asthma; Eosinophilic, Airway Remodeling | Phase 4 | Completed | Aristotle University Of Thessaloniki | 36 | 2024-03-01 | 2026-10-28 |
| STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma Benralizumab - Severe Eosinophilic Asthma | Phase 3 | Completed | AstraZeneca | 504 | 2024-02-28 | 2026-09-03 |
| AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma AD17002, Placebo - Eosinophilic Asthma | Phase 1 / Phase 2 | Completed | Advagene Biopharma Co. Ltd. | 40 | 2023-11-27 | 2025-09-10 |
| Dupilumab Efficacy on Bronchial Inflammation, Small Airways Disfunction and Mucous Secretion Dupilumab - Asthma; Eosinophilic | Unknown | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 30 | 2023-10-01 | 2024-10-04 |
Showing 20 of 103. Sign in to see all of them.
Asthma (57) · Churg-Strauss Syndrome (4) · Lung Diseases (3) · Airway Remodeling (2) · Eosinophilia (2) · Hypereosinophilic Syndrome (2) · Inflammation (2) · Nasal Polyps (2) · Pulmonary Disease, Chronic Obstructive (2) · Airway Obstruction (1) · Anxiety Disorders (1) · Aspergillosis, Allergic Bronchopulmonary (1) · Bronchial Diseases (1) · Chronic Disease (1)
Hematologic Diseases (103) · Hemic and Lymphatic Diseases (103) · Leukocyte Disorders (103) · Respiratory Tract Diseases (102) · Eosinophilia (101) · Hypereosinophilic Syndrome (101) · Lung Diseases (100) · Immune System Diseases (60) · Hypersensitivity (59) · Hypersensitivity, Immediate (59) · Respiratory Hypersensitivity (58) · Bronchial Diseases (56) · Lung Diseases, Obstructive (56) · Pathological Conditions, Signs and Symptoms (11) · Pathologic Processes (6)
mepolizumab (21) · benralizumab (13) · reslizumab (6) · Antibodies, Monoclonal, Humanized (5) · Albuterol (3) · Biological Products (2) · Injections (2) · Omalizumab (2) · Prednisolone (2) · dupilumab (2) · heat-labile enterotoxin, E coli (2) · (5-fluoro-2-methyl-3-quinolin-2-ylmethylindo-1-yl)acetic acid (1) · Allergens (1) · Antigens, Dermatophagoides (1) · Azithromycin (1)
AstraZeneca (17) · GlaxoSmithKline (9) · Teva Branded Pharmaceutical Products R&D, Inc. (5) · Areteia Therapeutics (4) · Hospices Civils de Lyon (3) · University Hospital Southampton NHS Foundation Trust (3) · Advagene Biopharma Co. Ltd. (2) · Aristotle University Of Thessaloniki (2) · Chiesi Farmaceutici S.p.A. (2) · McMaster University (2) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (2) · University Hospital, Lille (2) · AnaptysBio, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Attikon Hospital (1)
United States (29) · United Kingdom (24) · France (21) · Canada (20) · Germany (18) · Spain (16) · Argentina (14) · Poland (14) · Italy (12) · South Korea (11) · Russia (10) · Ukraine (10) · Belgium (9) · Brazil (9) · China (8)
Min Zhang, MD (2) · Qinghong Zhou, MD (2) · Xin Zhou, MD (2) · Adel Mansur (1) · Adelmir Machado, MD (1) · Adnan Azim, MBBS (1) · Alcindo Cerci Neto, MD (1) · Audrey Lehmann, Ph (1) · Bruce Randazzo, MD (1) · Celeste Porsbjerg, MD, PhD (1) · Christian Pedersen, MD (1) · Christian von Buchwald (1)
PMID 39393433, PMID 25736990, PMID 28159511, PMID 30193936, PMID 30346831, PMID 30964365, PMID 31262379, PMID 31626990, PMID 31798645, PMID 12045120, PMID 21037369, PMID 22016484, PMID 25614171, PMID 25858909, PMID 27018175, PMID 27056586, PMID 27239557, PMID 27820746, PMID 28395936, PMID 28433687, PMID 28461289, PMID 28583260, PMID 29221581, PMID 29290515, PMID 29453280, PMID 29949045, PMID 30876830, PMID 31047111, PMID 31251094, PMID 31362741, PMID 31507641, PMID 31659803, PMID 32101904, PMID 32762056, PMID 33369570, PMID 33971856, PMID 34098955, PMID 34158028, PMID 34172470, PMID 35177038, PMID 35248549, PMID 35283104, PMID 36781102, PMID 37131265, PMID 37334358, PMID 37343842, PMID 38071986, PMID 38595692, PMID 39741370, PMID 41304949
2015 (4), 2014 (2), 2016 (2), 2018 (2), 2017 (1), 2019 (1), 2023 (1)